Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >102 cm (compared with ≤25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS.

中文翻译：

---

REPRIEVE 试验参与者识别跨性别谱系的特征。

由于跨越跨性别谱系 (PATS) 的人是人类免疫缺陷病毒 (HIV) 的关键人群，但在 HIV 和心血管研究中的报道不足，因此我们旨在在 REPRIEVE 全球临床试验 (n = 7770) 中描述这一人群的特征。对收集性别认同的接受度很高 (96%)。PATS 的总体参与率为 1.7%，出生男性为 2.4%，出生女性为 0.3%，并且因地理区域而异（从撒哈拉以南非洲的 0% 到高收入地区的 2.3%）。百分之三十的出生男性 PATS 被确定为跨性别者以外的人。一些特征因性别而异。最值得注意的是，接受性别肯定治疗的出生男性 PATS 中有 38% 的腰围 >102 厘米（相比之下，其他组的腰围≤25%）。鉴于 PATS 是重点人群，